Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI). It has been found that fluvoxamine reduces inflammatory cytokine production by binding to sigma-1 receptors in immune cells. This is FDA approved for the treatment of obsessive-compulsive disorder. It is still currently undergoing studies to determine the effectiveness thereof in Covid-19. (Covid-19 Treatment guidelines).

https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/fluvoxamine/